image
Healthcare - Medical - Diagnostics & Research - NASDAQ - US
$ 17.6
0 %
$ 508 M
Market Cap
-89.58
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one CSTL stock under the worst case scenario is HIDDEN Compared to the current market price of 17.6 USD, Castle Biosciences, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one CSTL stock under the base case scenario is HIDDEN Compared to the current market price of 17.6 USD, Castle Biosciences, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one CSTL stock under the best case scenario is HIDDEN Compared to the current market price of 17.6 USD, Castle Biosciences, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart CSTL

image
$34.0$34.0$32.0$32.0$30.0$30.0$28.0$28.0$26.0$26.0$24.0$24.0$22.0$22.0$20.0$20.0$18.0$18.0$16.0$16.0$14.0$14.015 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '25
FINANCIALS
332 M REVENUE
51.09%
8.67 M OPERATING INCOME
112.75%
18.2 M NET INCOME
131.75%
64.9 M OPERATING CASH FLOW
1252.97%
-50.1 M INVESTING CASH FLOW
-209.81%
6.14 M FINANCING CASH FLOW
367.15%
88 M REVENUE
1.94%
-27.9 M OPERATING INCOME
-689.58%
-25.8 M NET INCOME
-269.53%
-6.04 M OPERATING CASH FLOW
-24.77%
-22.4 M INVESTING CASH FLOW
-388.75%
-1.55 M FINANCING CASH FLOW
71.16%
Balance Sheet Castle Biosciences, Inc.
image
Current Assets 360 M
Cash & Short-Term Investments 293 M
Receivables 51.2 M
Other Current Assets 15.8 M
Non-Current Assets 171 M
Long-Term Investments 0
PP&E 62.7 M
Other Non-Current Assets 108 M
55.18 %9.64 %2.98 %11.80 %20.40 %Total Assets$531.2m
Current Liabilities 49.4 M
Accounts Payable 6.9 M
Short-Term Debt 278 K
Other Current Liabilities 42.2 M
Non-Current Liabilities 26 M
Long-Term Debt 9.74 M
Other Non-Current Liabilities 16.3 M
9.15 %55.99 %12.92 %21.57 %Total Liabilities$75.4m
EFFICIENCY
Earnings Waterfall Castle Biosciences, Inc.
image
Revenue 332 M
Cost Of Revenue 60.2 M
Gross Profit 272 M
Operating Expenses 263 M
Operating Income 8.67 M
Other Expenses -9.58 M
Net Income 18.2 M
350m350m300m300m250m250m200m200m150m150m100m100m50m50m00332m(60m)272m(263m)9m10m18mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
81.87% GROSS MARGIN
81.87%
2.61% OPERATING MARGIN
2.61%
5.49% NET MARGIN
5.49%
4.00% ROE
4.00%
3.43% ROA
3.43%
1.52% ROIC
1.52%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Castle Biosciences, Inc.
image
40m40m30m30m20m20m10m10m00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)2018201820192019202020202021202120222022202320232024202420252025
Net Income 18.2 M
Depreciation & Amortization 16 M
Capital Expenditures -28.3 M
Stock-Based Compensation 50.3 M
Change in Working Capital -14.1 M
Others -3.89 M
Free Cash Flow 36.5 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Castle Biosciences, Inc.
image
Wall Street analysts predict an average 1-year price target for CSTL of $38 , with forecasts ranging from a low of $30 to a high of $45 .
CSTL Lowest Price Target Wall Street Target
30 USD 70.45%
CSTL Average Price Target Wall Street Target
38 USD 115.91%
CSTL Highest Price Target Wall Street Target
45 USD 155.68%
Price
Max Price Target
Min Price Target
Average Price Target
4545404035353030252520201515Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 11
6. Ownership
Insider Ownership Castle Biosciences, Inc.
image
Sold
0-3 MONTHS
329 K USD 1
3-6 MONTHS
2.36 M USD 4
6-9 MONTHS
1.99 M USD 4
9-12 MONTHS
1.51 M USD 4
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Castle Biosciences' Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards® Gold-level Stevie® Award recognizes Maetzold's transformative leadership in the healthcare industry, including molecular diagnostics and precision medicine FRIENDSWOOD, Texas, June 04, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its founder, president and chief executive officer Derek Maetzold has been awarded a distinguished Lifetime Achievement Award in the Management: Business Products Industries category in the 23rd Annual American Business Awards. The American Business Awards recognizes outstanding business performances in the United States. globenewswire.com - 1 week ago
New Data at ASCO 2025 Affirms DecisionDx®-Melanoma's Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival Outcomes FRIENDSWOOD, Texas, May 29, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will present novel research aimed at enhancing the clinical management of patients with cutaneous melanoma (CM) and uveal melanoma (UM) at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 30-June 3, 2025, in Chicago. This includes the latest findings from Castle's ongoing collaboration with the National Cancer Institute's Surveillance, Epidemiology and End Results (NCI's SEER) Program Registries affirming the significant, independent risk stratification provided by DecisionDx-Melanoma in an expanded, real-world cohort of more than 13,500 patients who received the test as part of their melanoma care. globenewswire.com - 2 weeks ago
Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference Castle's executive management will present a company overview at the 2025 Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 7:35 am ET globenewswire.com - 3 weeks ago
Real-World Study Confirms Long-Term Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class Result FRIENDSWOOD, Texas, May 09, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data from the first independent validation of the recently published Collaborative Ocular Oncology Group Study No. 2 (COOG2.1) by Harbour et al.1 The data, from a real-world cohort of 1,297 patients with uveal melanoma (UM), was presented at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting in Salt Lake City. globenewswire.com - 1 month ago
Castle Biosciences Celebrates Skin Cancer Awareness Month Castle continues its ongoing patient advocacy partnerships and highlights cancer journey to drive education and awareness for Skin Cancer Awareness Month globenewswire.com - 1 month ago
Castle Biosciences, Inc. (CSTL) Q1 2025 Earnings Call Transcript Castle Biosciences, Inc. (NASDAQ:CSTL ) Q1 2025 Earnings Conference Call May 5, 2025 4:30 PM ET Company Participants Camilla Zuckero - Vice President of Investor Relations and Corporate Affairs Derek Maetzold - Founder, President & Chief Executive Officer Matthew Goldberg - Senior Vice President, Medical Frank Stokes - Chief Financial Officer Conference Call Participants Sung Ji Nam - Scotiabank Kyle Mikson - Canaccord Puneet Souda - Leerink Partners Tom Peterson - Baird Paul Knight - KeyBanc Capital Markets Subbu Nambi - Guggenheim Mason Carrico - Stephens Thomas Flaten - Lake Street Mark Massaro - BTIG Operator Good afternoon and welcome to Castle Biosciences First Quarter 2025 Conference Call. As a reminder, today's call is being recorded. seekingalpha.com - 1 month ago
Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.09 per share a year ago. zacks.com - 1 month ago
Castle Biosciences Reports First Quarter 2025 Results Q 1 2025 revenue increased 21% over Q 1 2024 to $88 million Q 1 2025 total test reports for our core revenue drivers (DecisionDx ® -Melanoma, DecisionDx ® -SCC, TissueCypher ® ) increased 33% over Q 1 2024 Raising full-year 2025 revenue guidance to $287-297 million from $280-295 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, May 05, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the first quarter ended March 31, 2025. globenewswire.com - 1 month ago
Castle Biosciences to Acquire Previse Expected to complement Castle's current gastroenterology franchise Adds methylation technology developed at the Johns Hopkins University School of Medicine and additional technologies in development FRIENDSWOOD, Texas, May 05, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced it has signed a definitive agreement to acquire Capsulomics, Inc., d/b/a Previse. Previse is a gastrointestinal health company with a primary focus on chronic acid reflux related diseases, including esophageal cancer. globenewswire.com - 1 month ago
New Data at DDW 2025 Further Demonstrates the TissueCypher® Test's Ability to Identify Patients at Increased Risk for Developing Esophageal Cancer Additionally, an expert physician panel convened by EndoscopyNow will host a product theater on Sunday, May 4, at 2:45 p.m. Pacific Time, titled, “The Time is Now: A Clinical Practice Model to Help Prevent Progression from Barrett's to EAC” FRIENDSWOOD, Texas, May 02, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share new data on its TissueCypher Barrett's Esophagus test via two posters at the Digestive Disease Week® (DDW 2025) Annual Meeting, being held May 3-6 in San Diego. globenewswire.com - 1 month ago
New Study Shows Castle Biosciences' DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity Patients identified as low risk by DecisionDx-Melanoma had a 2.8% sentinel lymph node (SLN) positivity rate, well below the National Comprehensive Cancer Network® (NCCN) guidelines' 5% threshold to forgo sentinel lymph node biopsy (SLNB) surgery FRIENDSWOOD, Texas, April 30, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a new study in Cancer Diagnosis & Prognosis demonstrating that DecisionDx-Melanoma outperforms both American Joint Committee on Cancer (AJCC) staging and the CP-GEP test (clinicopathological and gene expression profiling model) in identifying patients at low risk of SLN positivity who may consider forgoing SLNB surgery.1 “When relying on genomic testing to guide critical decisions about procedures like SLNB, a test must demonstrate exceptional accuracy in identifying patients with minimal risk of metastasis," said Peter A. Prieto, M.D. globenewswire.com - 1 month ago
DecisionDx®-Melanoma Test Ordered More Than 200,000 Times for Patients Diagnosed with Cutaneous Melanoma FRIENDSWOOD, Texas, April 28, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its achievement of surpassing a significant milestone of 200,000 DecisionDx-Melanoma clinical test orders. DecisionDx-Melanoma is a 31-gene expression profile test that provides comprehensive, personalized results designed to improve risk-aligned management decisions for patients with stage I-III cutaneous melanoma. globenewswire.com - 1 month ago
8. Profile Summary

Castle Biosciences, Inc. CSTL

image
COUNTRY US
INDUSTRY Medical - Diagnostics & Research
MARKET CAP $ 508 M
Dividend Yield 0.00%
Description Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
Contact 505 South Friendswood Drive, Friendswood, TX, 77546 https://castlebiosciences.com
IPO Date July 25, 2019
Employees 784
Officers Dr. Matthew Goldberg M.D. Senior Vice President of Medical Ms. Camilla Zuckero Vice President of Investor Relations & Corporate Affairs Mr. Kevin Doman Vice President of Sales Dr. Jay Braxton Pharm.D. Vice President of Marketing & Brand Manager of Uveal Melanoma (UM) Ms. Keli Greenberg Vice President of Human Resources Mr. Derek J. Maetzold Founder, Chief Executive Officer, President & Director Mr. Frank Stokes Chief Financial Officer & Treasurer Mr. Tobin W. Juvenal Chief Commercial Officer Ms. Kristen M. Oelschlager R.N. Chief Operating Officer